Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
复制标题
DOI：
10.1016/j.jaci.2021.05.029
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Freund NT
中科院分区：
文献类型：
--
作者：
Hagin D;Freund T;Navon M;Halperin T;Adir D;Marom R;Levi I;Benor S;Alcalay Y;Freund NT
2020年12月中旬，以色列在全国范围内开展了针对2019冠状病毒病（COVID-19）的大规模疫苗接种活动。在最初的几周里，医务人员、老年人和慢性病患者被优先考虑。因此，鼓励原发性和继发性免疫缺陷患者接种疫苗。尽管基于RNA的COVID-19疫苗的有效性已在普通人群中得到证实，但其在先天性免疫缺陷（IEI）患者中的有效性和安全性知之甚少。我们的目的是评估IEI患者队列对COVID-19疫苗的体液和细胞免疫应答。共招募了26名成年患者，并在第二剂Pfizer-BioNTech COVID-19疫苗接种后2周从他们中收集血浆和外周血单核细胞。通过检测抗SARS-CoV-2刺突（S）受体结合域和抗核衣壳抗体滴度，并通过抑制受体结合域-血管紧张素转换酶2结合来评价中和能力，评价体液应答。通过使用ELISpot评估细胞免疫应答，估计响应于合并的SARS-CoV-2 S-或M-肽的IL-2和IFN-γ分泌。我们的队列包括18例主要抗体缺乏症患者，2例联合免疫缺陷，3例免疫失调，3例其他基因诊断。其中22人正在接受免疫球蛋白替代治疗。在26例患者中，18例发生特异性抗体应答，19例显示S肽特异性T细胞应答。无患者报告重大不良事件。用IEI疫苗接种患者是安全的，大多数患者能够产生疫苗特异性抗体应答、S蛋白特异性细胞应答或两者兼而有之。
In mid-December 2020, Israel started a nationwide mass vaccination campaign against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, elderly citizens, and patients with chronic diseases were prioritized. As such, patients with primary and secondary immunodeficiencies were encouraged to receive the vaccine. Although the efficacy of RNA-based COVID-19 vaccines has been demonstrated in the general population, little is known about their efficacy and safety in patients with inborn errors of immunity (IEI). Our aim was to evaluate the humoral and cellular immune response to COVID-19 vaccine in a cohort of patients with IEI. A total of 26 adult patients were enrolled, and plasma and peripheral blood mononuclear cells were collected from them 2 weeks following the second dose of Pfizer-BioNTech COVID-19 vaccine. Humoral response was evaluated by testing anti–SARS-CoV-2 spike (S) receptor-binding domain and antinucleocapsid antibody titers and evaluating neutralizing ability by inhibition of receptor-binding domain–angiotensin-converting enzyme 2 binding. Cellular immune response was evaluated by using ELISpot, estimating IL-2 and IFN-γ secretion in response to pooled SARS-CoV-2 S- or M-peptides. Our cohort included 18 patients with a predominantly antibody deficiency, 2 with combined immunodeficiency, 3 with immune dysregulation, and 3 with other genetically defined diagnoses. Twenty-two of them were receiving immunoglobulin replacement therapy. Of the 26 patients, 18 developed specific antibody response, and 19 showed S-peptide–specific T-cell response. None of the patients reported significant adverse events. Vaccinating patients with IEI is safe, and most patients were able to develop vaccine-specific antibody response, S-protein–specific cellular response, or both.
登录
查看更多内容
影响因子：
82.9
作者：
Levine-Tiefenbrun, Matan;Yelin, Idan;Kishony, Roy
通讯作者：
Kishony, Roy
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
T细胞和抗体动力学描述了介导共证疗法个体中介导长期免疫反应的SARS-COV-2肽。
影响因子：
17.1
作者：
Bilich T;Nelde A;Heitmann JS;Maringer Y;Roerden M;Bauer J;Rieth J;Wacker M;Peter A;Hörber S;Rachfalski D;Märklin M;Stevanović S;Rammensee HG;Salih HR;Walz JS
通讯作者：
Walz JS
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group